AMAnthony Merlocco

Anthony Merlocco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anthony Merlocco has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sustained improvement in sickle cell cardiomyopathy after haematopoietic stem cell transplantation is superior to that with disease‐modifying therapy

    by Parul Rai, Subodh Selukar, Yu Bi, Shuyan Chen, Anthony Merlocco, Cara E. Morin, Chris Goode, Jeffrey A. Towbin, Mark Rushing, Michael A. Rebolledo, et al.

    Summary: Allogeneic haematopoietic stem cell transplantation (HSCT) is curative for sickle cell disease (SCD) ‐ a group of inherited haemoglobin disorders encompassing homozygous haemoglobin S (HbSS) and compound heterozygous sickling disorders, including haemoglobin SC disease (HbSC), haemoglobin S/β 0 ‐thalassaemia (HbSβ 0 ), haemoglobin S/β + ‐thalassaemia (HbSβ + ), etc., but its long‐term impact on SCD myocardial remodelling is incompletely characterized. We performed serial cardiac magnetic resonance imaging (CMR) and echocardiography in children and young adults with SCD undergoing matched‐sibling or haploidentical HSCT in a prospective clinical trial with up to 36 months of post‐HSCT follow‐up. CMR assessments were conducted before HSCT and through the post‐HSCT period. Echocardiographic parameters at 12 months post HSCT were compared with those of age‐matched participants receiving disease‐modifying therapies (DMTs). Among 20 HSCT recipients (mean age 14.8 years), CMR demonstrated progressive reductions in biventricular volumes and left atrial volume over 36 months, with preservation of ejection fraction. Extra‐cellular volume, a surrogate marker of myocardial fibrosis, showed significant improvement from baseline, having normalized in nearly all participants assessed at 36 months. Compared with age‐matched DMT recipients, HSCT recipients had lower tricuspid regurgitant jet velocity and improved diastolic parameters at 12 months post‐HSCT, with normalization of cardiac output on echocardiography. These findings demonstrate sustained reversal of myocardial fibrosis and structural cardiac remodelling after HSCT for SCD. HSCT may, therefore, modify the trajectory of SCD cardiomyopathy beyond the improvements achieved with current DMTs.

  • Open Access

    Ethical Considerations in Islet Xenotransplantation

    by Daniel J. Hurst, Alexa Tarzy, Christopher A. Bobier, Luz A. Padilla, Johannes Kögel, Anthony Merlocco, Raphael P. H. Meier

    For the management of type 1 diabetes, islet xenotransplantation has emerged as a potential alternative to lifelong insulin therapy or islet allotransplantation. However, this progress raises significant ethical questions that warrant further exploration. This article will examine the ethical landscape of islet xenotransplantation, highlighting points of convergence and distinction with solid organ xenotransplantation. We focus on four key areas: (i) animal welfare, including the ethical implications of sourcing large numbers of pigs per recipient; (ii) pediatric considerations, given the lifelong impact of early interventions, and the increasing prevalence and burden of pediatric diabetes; (iii) informed consent and obligations for long‐term monitoring including sample retention; and (iv) strategies for inclusive public and patient engagement to build trust and transparency.


  • Open Access

    Liver Xenotransplantation: Ethical and Societal Implications

    by Daniel J. Hurst, Christopher A. Bobier, Luz A. Padilla, Anthony Merlocco, Raphael P. H. Meier

    The shortage of transplantable livers and high waitlist mortality rates have accelerated the clinical translation of liver xenotransplantation. Recent milestones, including extracorporeal perfusion models and gene‐edited pig‐to‐human transplants in both decedents and living patients, indicate that clinical trials may be imminent. While the ethics of solid organ xenotransplantation generally—such as animal welfare, xenozoonosis, and informed consent—have been debated, the specific implications of liver xenotransplantation remain underexplored. This article examines these unique challenges. We argue that pediatric liver xenotransplantation research might proceed simultaneously with adult research due to high waitlist mortality among infants. In adults, we analyze how liver xenotransplantation intersects with historical controversies regarding patient selection, specifically concerning alcohol‐associated liver disease and hepatocellular carcinoma. We explore the ethical risks of a potential dual pathway allocation system that could bifurcate waitlists based on disease etiology, raising concerns regarding distributive justice and the stigmatization of addiction. Finally, we consider whether xenografts might serve as a trial of time for patients currently ineligible for allotransplantation.


  • Xenotransplantation and Disability Contraindications to Pediatric Heart Transplantation: Are We at the Horizon of Organ Transplantation for any Person That May Benefit?

    by Anthony Merlocco, Luz A. Padilla, Christopher A. Bobier, Nobuyuki Ikeda, Daniel J. Hurst

    If cardiac xenotransplantation (XTx) can resolve the critical shortage of human organs, then we have an ethical obligation to reconsider it for select pediatric patients who are currently ineligible for allotransplantation but who may still benefit from a transplanted organ. This is especially true for children with genetic diseases who are often excluded due to unfavorable risk‐benefit assessments rooted in the scarcity of donor hearts. While the overall potential of XTx remains uncertain, its ability to mitigate scarcity forces us to reevaluate who might benefit from a transplant. This commentary argues that if XTx resolves at least some concerns regarding immediate organ availability and quantity, then we should support further evaluation for transplantation in pediatric patients who may benefit but who were previously deemed ineligible for cardiac allotransplantation. While not all patients may cross the risk‐benefit threshold, many deserve at least this evaluation, and failing to even evaluate is rooted in disability bias. Primarily focusing on the precedent trisomy 21 (T21) patients and the evolution in perceptions of transplantation suitability, we argue that if these patients will physiologically be stable after XTx, then we should consider the benefits XTx could provide—prolonged survival, symptom resolution, and improved quality of life (QOL) even if baseline QOL is limited (as in patients with other disabilities)—as justifying the attendant risks. This argument may also extend beyond T21 to other patient populations with genetic conditions, including select patients with trisomy 18 (T18).

  • Response to Urschel et al

    by Daniel J. Hurst, Anthony Merlocco

  • Eosinophilic Myocarditis in Children From Toxocara Canis: A Case and Review of the Literature

    by Joe Stephenson, Mario O’cOnnor, Maria Hoyos, Anthony Merlocco, Jason Johnson, Hugo Martinez

  • Xenotransplantation as a business solution to the organ shortage

    by Christopher Bobier, Richard B. Gibson, Anthony Merlocco, Daniel Rodger, Daniel J. Hurst

    Xenotransplantation has the potential to alter the U.S. transplant system in profound ways. However, this emerging “spare parts” solution spearheaded by biotechnology companies raises concerns about its impact on the organ shortage, healthcare systems, population health, and health inequalities. We contend that xenotransplantation may have limited benefits in improving health, could prove prohibitively expensive for many, and may divert resources away from proven public health measures. Additionally, it carries the risk of perpetuating stigma. Xenotransplantation may thereby exacerbate existing healthcare inequities across racial, ethnic, socio‐economic, and geographic lines. To mitigate these risks, we contend that public health expert input is integral for xenotransplant policy development and outreach and that this underscores the importance of federal government investment in transplant infrastructure.


  • Open Access

    Palliative Care Referral Patterns and Implications for Standardization in Cardiac ICU

    by Arshia Madni, Jocelyn Matheson, Amanda Linz, Austin Dalgo, Rumana Siddique, Anthony Merlocco

    Evidence suggests that pediatric palliative care involvement (PPC) is beneficial to medically complex patients. Historically, PPC involvement has been overlooked or delayed and varies by institution but PPC awareness has increased in cardiovascular ICUs (CVICU) and so we investigated frequency and timeliness of PPC referral for patients dying in ICU. Retrospective study of pediatric cardiac patients experiencing death in ICU to review PPC presence and timing of initial PPC, most recent PPC, and interventions, therapies, CPR, and presence of do-not-resuscitate DNR discussion. Fifty-four patients died during a 5-year period aged 11d–17y (54% male). PPC involvement occurred in 40/54 (74%). Of those patients without PPC, the Center to Advance Palliative Care (CAPC) guidelines would have supported PPC in 11/14 (79%). DNR discussion was more likely in PPC patients (63% vs 14%; p = 0.0011), though often only on DOD. Comparing prior to DOD, PPC patients were still more likely to have DNR discussion (55% vs 0%; p = 0.0003). PPC patients were no less likely to have CPR on DOD (28% vs 43%, p = 0.29). PPC occurred frequently in patients experiencing death in CVICU. However, frequently the initial PPC occurred within a week or day of death. Patients without PPC would often qualify under published guidelines. Standardization, timing, and patient identification for PPC will expand efficacy in CVICU.


  • Open Access

    Pediatric Cardiac Xenotransplantation and Expanded Access: Ethical Considerations

    by Daniel J. Hurst, Christopher Bobier, Anthony Merlocco, Luz A. Padilla, Daniel Rodger, David Cleveland, John D. Cleveland

    Due to the current organ shortage waitlist, alternatives to allotransplantation are necessary. Xenotransplantation is currently being pursued as one such alternative in adults in need of kidney or heart transplantation. Cardiac xenotransplantation of genetically modified pig hearts has been conducted twice in adults under the United States Food and Drug Administration (FDA) expanded access criteria. Because of the shortage of transplantable hearts for children as well as the lack of mechanical circulatory support in this population, pediatric researchers are exploring FDA expanded access in high‐risk neonates and infants who lack alternative options for survival. The adult cardiac xenotransplantation experience with expanded access can provide lessons and highlight nuances for researchers preparing pediatric application. This includes aspects of informed consent, biosurveillance, and protection of bystanders from potential xenozoonoses.